Truist Securities Maintains Hold on Globus Medical, Lowers Price Target to $65
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Richard Newitter maintains a 'Hold' rating on Globus Medical (NYSE:GMED) and lowers the price target from $68 to $65.
August 07, 2023 | 2:29 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities has maintained a 'Hold' rating on Globus Medical and lowered the price target from $68 to $65.
The news directly pertains to Globus Medical as Truist Securities has maintained a 'Hold' rating on the company and lowered the price target. This could potentially impact investor sentiment and the stock's price in the short term, but the 'Hold' rating suggests that the overall outlook for the company remains stable.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100